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Bupropion Reduces some of the symptoms of Marihuana 
Withdrawal in chronic Marihuana Users: A pilot study
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Abstract: Bupropion’s (Zyban® SR) effectiveness to treat symptoms experienced in marihuana withdrawal was tested in a double-blind, 
placebo-controlled study with chronic, heavy marihuana users. Participants maintained their usual marihuana intake until Quit Day 
after which they were required to cease intake of THC products for 14 days. A Withdrawal Discomfort Score revealed that for 7 days 
immediately following cessation, placebo-treated subjects reported more symptoms than bupropion-treated subjects. Self-reported 
craving for marihuana increased for the placebo-treated group but not for those treated with bupropion. Measures of sleep and cognitive 
performance were not different between the two groups. Participants in the bupropion treatment arm were more likely to complete the 
study than those randomized to the placebo arm (50% completion for bupropion vs. 33% completion for placebo). These results suggest 
that bupropion may be useful for alleviating marihuana withdrawal symptoms and be useful in subject retention during long-term 
cessation programs.
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Introduction
This research studied the effectiveness of the anti-
depressant  bupropion  (in  the  sustained  release 
formula—Zyban® SR) to alleviate withdrawal symp-
toms in chronic marihuana users. Although evidence 
of a marihuana withdrawal syndrome has existed for 
many years1,2 the clinical significance of the condi-
tion and the role of the symptoms in relapse has been 
debated. Recently, the time course of the withdrawal 
syndrome  has  been  documented3,4  and  it  has  now 
been  demonstrated  that  the  marihuana  withdrawal 
syndrome may very well be an important factor in 
maintaining use and relapse.5–7 Several components 
of the withdrawal syndrome are believed to affect the 
ability of users to quit and to thwart the success of 
cessation attempts. For example, many users could 
not quit or quickly relapsed because they experienced 
significant physical tension, anxiety, irritability and 
insomnia.  Resuming  marihuana  smoking  alleviates 
these  symptoms,  which  are  very  similar  to  those 
observed after tobacco withdrawal—a condition for 
which bupropion has been shown to be effective.
Bupropion’s  effects  on  withdrawal  symptoms 
observed during marihuana cessation were reported by 
Haney et al.8 In an elegant in-patient crossover design 
with  non-treatment  seeking  individuals,  marihuana 
users  smoked  marihuana  cigarettes  repeatedly  over 
5 days then underwent abrupt cessation and observed 
for 12 days while being treated with either bupropion 
or placebo. They concluded that bupropion worsened 
the marihuana withdrawal syndrome. Participants’ self-
ratings of irritability, feeling miserable, restless, unmo-
tivated, and depressed were all greater in the bupropion 
phase than in the placebo phase. These authors con-
clude that bupropion may not be an effective pharma-
cotherapy for treating marihuana dependence.
Preliminary data from our laboratory (unpublished 
data) indicated that bupropion may be effective in reduc-
ing increases in dysphoric mood following marihuana 
withdrawal in a different paradigm. In an out-  patient 
setting  of  21  days  of  verified  abstinence,  ratings  of 
anxiety, irritability, and physical tension were collected. 
These mood effects were attenuated relative to the his-
torical cohort of subjects who were withdrawn without 
bupropion.4 Given the success of bupropion in tobacco/
nicotine cessation programs and our preliminary find-
ings,  we  embarked  to  test  whether  bupropion  would 
alleviate  withdrawal  symptoms  in  treatment-seeking 
  cannabis-dependent individuals in a cessation paradigm 
similar to that used for tobacco cessation programs.
Materials and Methods
Participants
Treatment  seeking,  chronic,  heavy  users  of  mari-
huana between the ages of 18 to 50 years old were 
recruited via newspaper advertisements, internet ads, 
and advertisements on a local radio station. After giv-
ing informed consent, potential participants received 
a  physical  examination  and  a  Structured  Clinical 
Interview for DSM-IV (SCID-IV).9 Participants had 
to be physically healthy and meet SCID-IV criteria 
for marihuana abuse and/or dependence.   Additionally, 
they had to have had at least 3 years of heavy use 
(smoke  5  out  of  7  days  per  week  or  greater  than 
25 times per month) and have experienced 2 or more 
negative symptoms in previous quit attempts. They 
could  not  meet  abuse  or  dependence  criteria  for 
any other drug (including nicotine). Forty-five (45) 
men and women signed informed consent and were 
screened. Fifteen were found ineligible or declined 
to  participate  further;  another  8  withdrew  consent 
after the baseline week leaving 22 to be randomized 
to either active medication or placebo treatment. Of 
the 22 randomized, 9 completed the study through the 
14 day withdrawal assessment period and were used 
for data analysis. These 9 completers consisted of 
5 men, 4 women, aged 31.2 ± 9.6 years old (range 20 to 
44 years). Two met criteria for marihuana abuse while 
the remaining met criteria for abuse and   dependence. 
They were at least daily smokers of marihuana with 
1 smoking 2 to 3 times/day and 3 others reporting 
smoking 3–4 times per day, and had smoked regularly 
for 3 to 20 years. All had attempted to quit at least 
once previously. All were regular, light to moderate 
drinkers of alcohol (1 or 2 drinks per week to 1–2 
drinks per day), moderate caffeine users (less than 
300 mg per day), and 2 were light tobacco users (less 
than 5 cigarettes per day). The study was approved 
by the McLean Hospital Institutional Review Board. 
Participants provided written informed consent before 
beginning and they were paid for their participation.
Materials
Daily diary
The diary contained a section for recording any and all 
drug use in the past 24-hour period (including the study Bupropion and marihuana withdrawal
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medication), a sleep log, and the Marijuana Withdrawal 
Checklist.5 The sleep log contained 5 questions and 2 
visual analog scales. The questions were: “What time 
did you go to bed last night?”, “How quickly did you 
fall asleep (in minutes)?”, “How many times did you 
wake up during the night for more than just a minute or 
two (list number and total time awake)?”, “What time 
did you wake up this morning?”, and “What time did 
you get out of bed this morning?”. The two visual ana-
log scales assessed the characteristics of the previous 
sleep period. In response to the question of “When you 
got up this morning, you felt:”, participants placed a 
mark along a 100 mm line anchored with “exhausted” 
on the left end and “refreshed” on the right end. In 
response  to  the  question  of  “Overall,  your  sleep 
last night was:”, participants placed a mark along a 
100 mm line anchored with “very restless” on the left 
and “very sound” on the right end. This diary incorpo-
rates aspects of sleep commonly assessed in clinical 
and research studies (cf10) and are components of most 
sleep diaries in current use. The Marijuana Withdrawal 
Checklist assessed mood and withdrawal symptoms.5 
It is comprised of 29 items rated on a 4-point scale 
(0-none to 3-severe). A withdrawal discomfort score is 
computed from 10 of the items found to be most sen-
sitive to subjective states following withdrawal from 
chronic marihuana use (maximum score of 30). The 
10 items for the discomfort score are: anger, craving 
for marihuana, depressed mood, decreased appetite, 
headaches, irritability, nervousness, restlessness, sleep 
difficulty, and strange dreams.
Assessment tests
A computerized performance assessment battery was 
used to assess a variety of cognitive performance abili-
ties including memory, reaction time, and spatial rec-
ognition. The specific tasks included simple reaction 
time (requiring the performer to press the space bar 
as soon as a snowflake appeared on the screen), logi-
cal reasoning (indicate whether a statement about the 
relationship between two symbols was true or false,11 
matching-to-sample (view a 6 × 6 block of red and 
green squares for 3 seconds and then indicate which of 
two choices presented after a 5-second delay matched), 
memory task (the performer studies a 6-letter string and 
then answers if the appearing letter was in the origi-
nal string or not), and a running memory continuous 
performance  (‘1-back’)  number  task  (the  performer 
indicates if the currently presented number is the same 
or different from the one just seen). The battery took 
approximately 20 minutes to complete.
Other assessments
Changes in self-reported depression and anxiety were 
assessed using the Beck Depression Inventory12 and 
Beck  Anxiety  Inventory.13  These  inventories  were 
completed once during the baseline period, on the 
first day of medication and then weekly (days 7, 14, 
and  21).  The  University  of  Rhode  Island  Change 
  Assessment (URICA) Scale14 (24-item version) was 
administered on the first and last day of the study.
Actiwatch
A  wrist-worn  activity  monitor  (Actiwatch®  Score, 
Respironics, Bend, OR) was used for measurements 
of activity and verification of sleep periods. Sleep 
periods were scored according to proprietary software 
which has been shown to be reliably correlated with 
polysomnoghraphic recordings in young to middle-
aged adults.15
Medication
Bupropion sustained release (Zyban® SR) tablets were 
taken by those randomized to the active medication 
group in the following manner: For days 1–3, 150 mg 
once a day and then 150 mg twice a day (mid morn-
ing and late afternoon) for the remainder of the study 
(days 4–21). This regimen is consistent with the man-
ufacturer’s and FDA guidelines for treating tobacco/
nicotine addiction. Bupropion tablets were repackaged 
into gelatin capsules for blind administration. Placebo 
consisted of identically appearing gelatin capsules that 
contained gelatin filler (Nature’s Way, 10 gr/650 mg). 
Additionally,  with  each  medication  administration, 
participants consumed an identically appearing cap-
sule that contained 25 mg of vitamin B2 (riboflavin). 
Riboflavin can be detected in the urine through the 
use of ultraviolet light fluorescence and was used as a 
measure of medication compliance.16
Procedure
The study was a between-subjects design where par-
ticipants were randomly assigned to receive either 
bupropion  or  placebo  following  a  7  day  baseline 
period (days −7 to −1; see Fig. 1). A double-blind 
regimen  of  either  placebo  or  bupropion  began  on 
Day 1 and continued for 21 days. Participants were Penetar et al
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allowed to continue their usual marihuana use until 
Day  8—Quit  Day,  after  which  no  further  intake 
was allowed. Allowing for a one week of treatment 
with medication before cessation of marihuana use 
is consistent with established guidelines for the use 
of bupropion in treating tobacco/nicotine addiction. 
Female participants were not using oral birth con-
trol medication but were required to use other forms 
of  contraception.  Urine  pregnancy  tests  were  per-
formed at each laboratory visit. Women completed 
a menstrual cycle diary and began the study on days 
5–14 of their cycle. Participants who used tobacco 
and caffeine continued their use at prestudy levels 
throughout the study. Participants were trained on 
the computerized performance tasks during the base-
line week in order to establish stable performance, 
and instructed on how to complete the daily diary.
Participants came to the laboratory daily Monday 
through Friday. They gave a urine sample that was 
analyzed  quantitatively  for  THC  metabolites  (see 
below) and for the presence/absence of other drugs of 
abuse (Instant-View® Multi-Drug Screen Urine Test, 
Alfa Scientific Designs, Inc). The urine was viewed 
under ultraviolet light for riboflavin fluorescence by 
two observers. Participants completed a computer-
ized  performance  assessment  battery.  Diaries  were 
collected and medication was dispensed.
Analysis of urine samples  
and verification of abstinence
Urine samples were sent to a commercial laboratory 
(Quest Diagnostics, Cambridge, MA) where they were 
screened by immunoassay for the THC metabolite 
11-nor-carboy-delta  9-tetrahydrocannabinol  (THC-
COOH). Urine creatinine concentrations were also 
measured to assess urine concentration. A threshold 
for detection of THC-COOH was 20 ng/mL. Samples 
positive for this metabolite underwent further analysis 
by gas chromatography-mass spectroscopy (GC/MS) 
to  obtain  quantitative  THC-COOH  concentration. 
Samples after Day 8 (Quit Day) were further assessed 
for evidence of new marihuana use. The operational 
definition for this criterion was that the cannabinoid/
creatinine ratio on a given day could not be greater 
than 50% higher from the ratio obtained in the previ-
ous day’s urine sample. This definition of new mari-
huana use is based on data from controlled clinical 
studies of urinary excretion profiles of creatinine and 
marihuana metabolites following marihuana admin-
istration in humans17–19 and was used in a previous 
study in this laboratory.4
Psychosocial support
Participants underwent weekly sessions of a motiva-
tional enhancement therapy (MET) that was adapted 
and used for marihuana dependence.20 This treatment 
was adapted from manuals used in Project Match21 and 
the CSAT Multi-Site Marihuana Treatment   Project.22 
Three individual MET sessions (once during the week 
before Quit Day and then once during each week of 
abstinence) were conducted by a psychologist trained 
in MET. MET has empirical support for both mari-
huana dependence23 and alcohol addiction.24
Data analysis
Data  were  analyzed  using  a  general  linear  model 
repeated measures analysis of variance (SPSS 13.0 for 
Mac OS X, Chicago, IL) using drug group and time 
as the main factors. Post hoc analyses were performed 
using Fischer’s least significant difference test when 
significant  main  effects  were  found.    Significance 
level was set at P , 0.05 for all tests. Effect size is 
reported  using  the  variance-accounted-for  statistic 
Partial Eta-Squared obtained from the SPSS output.
Medication 
Baseline
150 mg/day 
or placebo
150 mg twice a day or placebo   
−7  −1  1  23   4  5  67
Quit
day
8910 11 12 13 14 15 16 17 18 19 20 21
Marihuana use as usual No marihuana use 
Figure 1. Study schematic.
notes: Participants filled out daily diaries from baseline through day 21. Medication started 7 days before ‘Quit Day’ in a procedure mimicking that recom-
mended for treatment of tobacco cessation.Bupropion and marihuana withdrawal
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Results
Abstinence and medication compliance
Creatinine-normalized urinary levels for the primary 
THC metabolite are reported in Figure 2. Average 
metabolite levels ranged between 260 and 468 ng/mL 
during study days before Day 8-Quit Day. A sharp 
decline was observed in the first 2 days of abstinence 
but detectable levels were still evident (although con-
tinuing to decline) at the end of the second week of 
abstinence. Averaged levels during the last 5 days of 
the study were 42, 31, 29, 37, and 27 ng/mL. Urine 
samples collected at each laboratory visit were viewed 
by two observers for fluorescence. All samples were 
positive for riboflavin indicating recent ingestion of 
the medication. As expected, all urine samples were 
positive for THC metabolites; all samples were nega-
tive for other drugs of abuse.
Withdrawal discomfort score
The day by day averages of the 10 item withdrawal 
discomfort  score  calculated  from  the    Marijuana 
Withdrawal  Checklist  are  shown  on  Figure  3. 
Generally speaking, scores increased from baseline 
week through the end of the study (main effect for 
time: F(21,147) = 1.726, P = 0.033, η2
Partial = 0.198), 
although  overall,  there  was  no  significant  differ-
ence between the two groups. Analysis of percent 
change from baseline values revealed that following 
cessation of marihuana intake (days 8 through 21), 
discomfort  scores  increased  significantly  for  the 
placebo-treated subjects but not for the bupropion-
treated subjects.
craving scores
Similarly,  craving  scores  tended  to  increase  from 
baseline days through the end of the study, although 
this effect missed statistical significance (main effect 
for time: F(21,147) = 1.522, P = 0.078, η2
Partial = 0.179) 
(Fig. 3). However, a further analysis using percent 
change in scores revealed that placebo-treated subjects 
significantly increased their craving ratings follow-
ing marihuana cessation and these ratings remained 
significantly elevated from baseline for the two treat-
ment weeks (main effect for time: F(3,21) = 3.416, 
P = 0.036, η2
Partial = 0.328; time by group   interaction: 
F(3,21)  =  4.511,  P  =  0.014,  η2
Partial  =  0.392). 
  Bupropion-treated subjects did not show an increase 
in craving ratings, and furthermore, these ratings were 
significantly  lower  than  the  placebo-treated  group 
during the withdrawal weeks.
0
100
200
300
400
500
600
700
−7 12 3456 7891 01 11 21 31 41 51 61 71 81 92 02 1
Study day
Quit day
Creatinine-normalized THC-COOH Urinary Levels
n
g
/
m
L
−1
Figure 2. Urinary Thc metabolite levels for 9 participants completing the study.
note: Values dropped sharply after ‘Quit Day’ and continued to decrease slowly but were still detectable at day 21.Penetar et al
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Beck Depression and Anxiety 
inventories; URicA
Scores on the depression inventory were below 10 
with one exception for a placebo subject during base-
line  and  remained  low  throughout  the  study  (data 
not shown). No significant changes were observed 
for study phase or medication treatment. Scores on 
the  anxiety  inventory  similarly  were  low  (below 
6 except for the same subject during baseline) but did 
show a significant decrease overall through the study 
[F(4,28) = 3.856, P = 0.013, η2
Partial = 0.355]. Scores 
were significantly lower after one week of withdrawal 
in comparison to baseline for both groups. There were 
no differences due to medication treatment. Analysis 
of the Readiness to Change score from the URICA 
scale did not reveal a significant time effect or group 
difference.
Sleep measures
Analysis of the actiwatch recordings and daily diary 
entries indicated that total sleep time decreased slightly 
for both groups during the first withdrawal week and 
recovered  somewhat  during  the  second  withdrawal 
week (data not shown). From the diary entries, par-
ticipants  slept  on  the  average  of  7.3  hours  during 
baseline, 6.8 hours (30 minutes less) during the first 
week of withdrawal, and 7 hours during the second 
week of withdrawal. These changes were not statisti-
cally   significant. Both groups showed similar patterns 
and there were no significant differences between the 
groups. Latency to fall asleep did not vary by drug group 
or study week, but during the first week of withdrawal, 
once participants fell asleep, those in the bupropion 
group tended to sleep better: wake after sleep onset 
(WASO)  analysis  showed  that  the  bupropion  group 
was awake 10.1% of the sleep period vs. 14.2% for the 
placebo-treated group. This difference was not statisti-
cally significant. Visual analog scale ratings of sleep 
quality remained steady throughout the study. Average 
weekly ratings of feeling exhausted to refreshed upon 
awakening were between 61 and 65 (on a 100 mm 
line). Average weekly ratings of feeling exhausted to 
Withdrawal discomfort Score
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Craving to smoke marihuana
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Figure 3. Daily withdrawal discomfort and craving scores.
notes: The withdrawal discomfort is a composite score of 10 items from the behavioral checklist of symptoms with a maximum score or 30. craving to 
smoke marihuana was rated on a 0 to 3 point scale from ‘none’ to ‘severe’.Bupropion and marihuana withdrawal
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refreshed upon awakening were between 61 and 65 (on 
a 100 mm line). Average weekly ratings of restless to 
sound overall sleep were between 66 and 73. Stanford 
Sleepiness Scale ratings decreased slightly (indicating 
more alertness) over the course of the study (from an 
average of 2.6 in baseline to 2.0 in the second week 
of  withdrawal)  but  were  not  statistically  significant 
between the groups or over the study weeks.
cognitive tests
Performance on two of the cognitive assessment tests 
improved  over  the  study  weeks. Throughput  mea-
sures of performance (ie, correct responses per unit 
of time) on the continuous performance (‘1-back’) 
task  improved  from  an  average  of  102  correct 
responses per minute during baseline to 124 during 
the second week of withdrawal (main effect for time: 
F(3,18) = 25.92, P , 0.001, η2
Partial = 0.812; data not 
shown). Logical Reasoning values increased from an 
average of 28.4 during baseline to 36.4 (main effect 
for time: F(3,18) = 5.524, P = 0.007, η2
Partial l = 0.479; 
data not shown). Performance on the other tests also 
showed generally increasing scores, but these changes 
were not statistically significant. There were no sta-
tistically significant differences between the placebo- 
and bupropion-treated groups.
completion analysis
Twenty-two (22) participants completed the baseline 
week and were randomized to a treatment group. Of the 
10 randomized to the bupropion treatment, 50% finished 
the 21-day study. Of the 12 randomized to the placebo 
treatment, 4 completed the study (33% completion).
Discussion
Bupropion has been shown to be effective in reducing 
withdrawal symptoms and reducing cravings when 
quitting tobacco cigarette smoking.25,26 One rationale 
for the use of bupropion to treat cannabis dependence 
and withdrawal symptoms rests on the similarity of 
withdrawal symptoms between cigarettes and canna-
bis use.27,28 However, reports on the use of bupropion 
to treat marihuana withdrawal symptoms have been 
negative. Carpenter et al29 concluded that bupropion 
did  not  lessen  withdrawal  symptoms  (specifically 
  irritability)  during  a  13-week  outpatient  treatment 
study.  Haney  et  al’s8  in-patient  study  of  enforced 
  marihuana  smoking  followed  by  placebo  smoking 
showed that bupropion increased rather than decreased 
some withdrawal symptoms. Both sets of researchers 
conclude that bupropion would have limited, if any, 
usefulness  in  treating  marihuana  dependence.  The 
present study tested bupropion in a paradigm mod-
eled after smoking cessation programs and assessed 
effectiveness during the period when symptoms are 
typically  the  strongest3  and  demonstrated  that  two 
important  measures  of  subjective  marihuana  with-
drawal effects—a composite withdrawal discomfort 
score and self-  reported cravings to smoke—increased 
for  participants  treated  with  placebo  but  remained 
constant for the bupropion-treated participants during 
a 14-day withdrawal period.
The selection of participants for this study included 
individuals who met DSM-IV criteria for abuse and/
or dependence, but more importantly, potential par-
ticipants were queried further to insure that regardless 
of whether they strictly met abuse and/or dependence 
criteria, they had had difficulty in reducing or stop-
ping their use in the past. We wanted to maximize our 
efforts to study individuals who had experienced dis-
cernable (and unpleasant) withdrawal efforts in pre-
vious attempts to cut down or stop using marihuana. 
We felt that the best opportunity to assess bupropion’s 
effects would be in individuals who had problems in 
the past and not simply including individuals who 
met DSM-IV criteria.
A limitation of the study is its small sample size. 
We designed the assessment to include only individu-
als  who  completed  the  14-day  withdrawal  period. 
A more definitive assessment of bupropion’s ability 
to alter marihuana withdrawal effects will need to 
include a larger sample size of completers and per-
haps the incorporation of more sophisticated statistical 
methods to handle the data from the non-completers.
Long-term,  chronic  marihuana  intake  has  been 
shown to affect cognitive abilities. Solowij et al30 com-
pared performance on 9 standard neuropsychological 
tests of attention, memory, and executive functioning 
in three groups of subjects: long-term users with a 
mean of over 20 years of regular use (at least twice per 
month), short-term users with a mean of 10 years of use, 
and nonusers. In comparison to nonusers or short-term 
users, long-term users performed significantly poorer 
on verbal learning and time estimation tasks. Despite 
these demonstrated effects of such use, it appears that 
they  are  not  permanent.  Pope  et  al,31  for  example, Penetar et al
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studied cognitive performance in long-term, chronic 
users recruited to stop smoking and refrain from all 
THC intake for 28 days. Tests included assessments 
of memory, attention, abstraction ability, and ability 
to learn and recall visuospatial information. Current 
users performed poorer than former users or control 
subjects for the first 7 days of withdrawal, consistent 
with residual levels of THC remaining in the body. 
By day 28 however, there were no differences among 
the  groups,  indicating  that  impaired  cognitive  per-
formance is a function of recent marihuana use. The 
results  of  the  present  study  are  in  agreement  with 
gradual improvements in psychomotor and cognitive 
performance reported following cessation of chronic 
drug intake. Performance on the tests included in the 
battery used in the current study did not show any 
withdrawal-related  decrease:  performance  was  not 
poorer during withdrawal for either treatment group. 
These results show that the ability of these tests to be 
indicative of an acute withdrawal syndrome appears 
to be limited, but may be more useful for assessing 
long-term changes following cessation of use.
Changes in sleep patterns have long been associ-
ated with withdrawal from chronic drug use. Early 
studies by Feinberg et al,32,33 Jones et al,1 and Kara-
can et al34 showed sleeplessness associated with an 
increase in rapid eye movement sleep following the 
abrupt  termination  of  access  to  marihuana.  More 
recently, Budney et al6 reported that ‘sleep difficulties’ 
were recorded by over 40% of their subjects, although 
the exact nature of these difficulties were not detailed. 
Haney et al’s7,35 in-patient studies reported that with-
drawal from 4 days of oral THC administration, but 
not 4 days of smoked marihuana, produced significant 
disruptions in sleep: decreases in self-reported quan-
tity and quality of sleep were observed. The changes 
observed during withdrawal in the current study were 
not statistically significant. This is somewhat surpris-
ing given the previous reports of sleep alterations dur-
ing withdrawal. The reasons for the lack of significant 
changes need further examination.
The  higher  completion  rate  by  the  bupropion 
group  is  encouraging.  It  is  possible  that  those 
treated  with  placebo  experienced  more  severe 
withdrawal symptoms overall and thus were more 
likely to drop out, but this will require additional 
experimentation. Success in cessation treatment is 
often related to the ability to keep patients enrolled 
and keep receiving pharmacotherapy and psycho-
social  support.36  If  bupropion  is  alleviating  some 
of  the  withdrawal  symptoms,  this  may  contribute 
to  improved  retention.  Bupropion  is  a  prescrip-
tion  medication  that  should  not  cause  problems 
in  marihuana-dependent  but  otherwise  healthy 
  individuals. When prescribed at the recommended 
doses for nicotine withdrawal, side effects included 
a low incidence of reported dry mouth, skin rashes, 
shakiness,  and  dizziness.  Insomnia  was  reported 
by 31% of those taking the medication in a dose-
response trial.37 More serious side effects such as 
seizures are possible and therefore the medication is 
not recommended for individuals with a history of 
seizures or in bulimia patients, especially at higher 
than the recommended doses. Our experience (in an 
admittedly small sample) would indicate that when 
prescribed at the recommended doses, bupropion is 
well tolerated in marihuana using individuals.
This small sample study indicates that bupropion 
may be effective in relieving some withdrawal symp-
toms that occur following cessation of chronic mari-
huana use. Changes observed in withdrawal discomfort 
scores and cravings in the placebo-treated group were 
not observed in the bupropion-treated group. These 
are preliminary but encouraging results for the use of 
bupropion as a potential pharmacotherapeutic agent 
in the treatment of marihuana withdrawal.
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